INFO & CONTACTS:  +39 02 2390 1

A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer (61186372GIC2002 – Origami 1)

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Pietrantonio Filippo

Main Facility: Oncologia Medica Gastroenterologica

Drug: Amivantamab sottocute (farmaco sperimentale)

Pathologies: Colorectal cancer (CRC)

ClinicalTrials.gov: Read the details about clinical trials

This is an open-label, multicenter, Ph1b/2 study.

The study is currently open for COHORT F, which is investigating the antitumor activity of subcutaneous amivantamab in addition to standard therapy (mFOLFOX6) for the treatment of patients with previously untreated unresectable or metastatic right-sided colorectal cancer.

The primary objective for Cohort F participants is to characterize the safety of subcutaneous amivantamab in addition to standard chemotherapy in patients with metastatic colorectal cancer (mCRC). The secondary objective is to evaluate the antitumor activity of Cohort F participants.

 

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe